H igh-density lipoprotein cholesterol (HDL-C) and apolipoprotein A-I (ApoA-I) concentrations are strong predictors of risk for cardiovascular disease (CVD).
1,2 The development of a well-tolerated agent that can significantly elevate serum HDL-C levels remains a therapeutic target. Statins raise HDL-C only modestly, and it is not clear whether that effect plays a role in the success of statins in CVD reduction. Niacin increases HDL-C significantly, but 2 recent studies where niacin was added to statin treatment did not reduce CVD. 3, 4 Fibrates increase HDL-C moderately, depending on baseline triglycerides, but studies of fibrates and CVD reduction have produced mixed results. 5, 6 There is one large ongoing trial to determine whether CVD can be reduced by increasing HDL-C with inhibitors of cholesteryl ester transfer protein; three previous trials with this class of drug, however, have failed 7, 8 (Press Release: Eli Lilly and Co. October 12, 2015) . Although niacin may increase the production of ApoA-I, 9 the other HDL-raising drugs do not. Relevant to this point, data from mouse models indicate that when ApoA-I synthesis is increased by genetic approaches, atherosclerosis is reduced. [10] [11] [12] Importantly, short-term administration of ApoA-I has provided promising, but not definitive, evidence of beneficial effects on atherosclerotic lesions in animals [13] [14] [15] and in humans. [16] [17] [18] Low levels of HDL-C are common in the people with defective insulin signaling, eg, metabolic syndrome and type 2 diabetes mellitus. 19, 20 Although the hypertriglyceridemia common to these disorders drives increased cholesteryl ester transfer protein-mediated exchange of HDL cholesteryl esters for triglycerides from very low-density lipoproteins and chylomicrons, those pathways only account for about half of the inverse relationship between triglycerides and HDL-C. Mouse models of defective insulin signaling, such as insulin receptor (InsR) liver-specific insulin receptor knockout (LIRKO) mice, 21 PI3K double knockout mice 21 and mice lacking hepatic Irs 1 and Irs 2, 22 all have reduced HDL-C levels in the The mechanism by which defective insulin signaling results in low levels of HDL-C remains to be determined.
To examine the role of insulin signaling in the regulation of HDL-C and ApoA-I levels, and based on our previous study in congenital LIRKO mice, 21 we created acute LIRKO mice by injecting a Cre adenovirus into InsR(fl/fl) (Lox) mice. Microarray analyses indicated that concomitant with reductions in ApoA-I levels in serum, the mice had marked reductions in the hepatic expression of ApoA-I. In addition, and to our surprise, the largest change in gene expression was that of type I deiodinase (Dio1), which was reduced by 90% in the acute LIRKO mice. Here, we present results of a series of in vivo and in vitro experiments demonstrating that Dio1 can regulate ApoA-I gene expression at the level of the promoter, and that this regulation is independent of previously demonstrated effects of thyroid hormone on ApoA-I gene expression. Importantly, reduced Dio1 expression resulted in reduced rates of ApoA-I synthesis and secretion from hepatocytes. Our results demonstrate a completely novel mechanism for the regulation of ApoA-I gene expression and provide new insights on the link between states of defective insulin signaling and reduced levels of plasma HDL-C and ApoA-I.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Acute and Chronic Loss of Hepatic InsRs Are Associated With Reductions in the Levels of HDL-C and ApoA-I, and the Expression of ApoA-I and Dio1
We reported previously that LIRKO mice have markedly reduced serum HDL-C levels. 21 In this study, we produced acute liver InsR depletion by injecting 10-week-old InsR (fl/fl) (Lox) mice with either an adenovirus carrying the Cre recombinase with the liver-specific albumin promoter (Ad-Cre) or a control adenovirus carrying LacZ (Ad-LacZ). Levels of liver InsR levels were determined by Western blotting of hepatic samples from Ad-LacZ and Ad-Cre-injected mice at day 3, day 6, and day 12. By 6 days after injection of Ad-Cre, hepatic InsR expression levels were reduced by 90% ( Figure 1A ). Fast protein liquid chromatography analysis revealed that both HDL-C and ApoA-I were significantly decreased in Lox mice infused with the Ad-Cre compared with Ad-LacZ injected mice ( Figure 1B ). As noted above, microarray analyses revealed that livers from the mice injected with Ad-Cre had marked reductions in the expression of ApoA-I and Dio1 ( Figure IA in the online-only Data Supplement); real-time quantitative polymerase chain reaction data confirmed these results ( Figure 1C ). Microarray analyses of other major genes involved in HDL-C metabolism, including SR-BI (scavenger receptor class B member 1), ABCA1 (ATP-binding cassette transporter-A1), and ABCG1 (ATP-binding cassette transporter-G1), did not show significant changes in Lox mice treated with Ad-Cre ( Figure IA in the online-only Data Supplement). Other lipid or lipoprotein-related genes that were affected by acute loss of InsR included ApoB, ApoAII, ApoCIII, ApoE, LDLR (lowdensity lipoprotein receptor) and LCAT (lecithin-cholesterol acyltransferase); they were all downregulated in the microarray analysis ( Figure IB in the online-only Data Supplement) and, except for ApoCIII, by quantitative polymerase chain reaction as well ( Figure IC in the online-only Data Supplement). Based on these findings, we returned to LIRKO mice and confirmed the reduced HDL-C levels we had reported previously ( Figure 1D) . 21 In addition, we found reduced ApoA-I levels in HDL fractions ( Figure 1D ). We also observed that ApoA-I mRNA and Dio1 mRNA levels were significantly decreased in LIRKO mice ( Figure 1E ). In our prior study, expression of constitutively active AKT reversed the low HDL-C in LIRKO mice 21 ; we repeated this and demonstrated a marked increase in Dio1 mRNA levels in LIRKO after administration of an adenovirus carrying constitutively active AKT ( Figure II in the online-only Data Supplement). These results are consistent with low levels of HDL-C and Dio1 mRNA levels present in AKT1/2 double knockout mice ( Figure IIIA and IIIB in the online-only Data Supplement).
In mammals, Dio1 is highly expressed in liver and has been widely thought to be an important source of 3,5,3′-triiodothyronine (T3) in the euthyroid state. However, mice lacking the type I deiodinase enzyme (D1) have no evidence of hepatic hypothyroidism and have normal plasma T3 levels. 23, 24 Indeed mice lacking all 3 types of deiodinase activity have a normal hepatic T3 content. 25 To test whether the reduced expression of hepatic Dio1 results in a reduced content of T3 in liver, we measured T3 content in the livers of LIRKO mice and their control Lox mice. There was no significant difference in liver T3 content between these 2 groups ( Figure IVA in the online-only Data Supplement). Importantly, the normal hepatic T3 content in LIRKO mice suggested that any mechanistic association of defective hepatic insulin signaling, reduced Dio1 expression, and low plasma HDL-C and ApoA-I levels might not involve the well-described effects of T3 on ApoA-I gene expression. 26 knockout mice (D1KO) mice. In D1KO mice, both HDL-C and HDL ApoA-I levels were reduced compared with wild-type controls ( Figure 2A ). Concomitant with these differences in blood levels, hepatic ApoA-1 mRNA levels were significantly reduced in D1KO mice ( Figure 2B ). Importantly, quantitative polymerase chain reaction of D1KO livers demonstrated that Acute and chronic loss of hepatic liver-specific insulin receptors (InsRs) are associated with reductions in high-density lipoprotein cholesterol (HDL-C), ApoA-I, and the expression of ApoA-I and Dio1. A, InsR levels were determined by Western blots of livers from acute liver-specific insulin receptor knockout (LIRKO) mice and their controls generated by injecting 5×10 9 viral particles of Ad-Cre or Ad-LacZ into 10-week-old Lox mice (n=3 per group). Livers were harvested at day 3, day 6, and day 11 after injections. B, Serum was obtained from 10-week-old Lox mice 6 d after injection with Ad-LacZ or Ad-Cre after a 6-h fast. 200 μL of pooled serum from mice (n=6 per group) was subjected to fast protein liquid chromatography (FPLC) to resolve lipoproteins and cholesterol was measured in each of the eluted fraction (top). The FPLC fractions representing HDL (fractions 27-33) were used for Western blotting of ApoA-I (bottom).The data shown are from 1 of 3 independent experiments. C, Livers (n=4-6 per group) were harvested 6 d after injection of Ad-LacZ or Ad-Cre into Lox mice.Real-time polymerase chain reaction (PCR) was used to verify microarray results showing significantly reduced hepatic ApoA-I and Dio1 expression levels in acute LIRKO mice. D, 200 μL of serum was pooled from 16-week-old LIRKO mice and Lox controls (n=5 per group) and lipoproteins were resolved by FPLC. Cholesterol and ApoA-I were determined as described in B. E. Liver ApoA-I mRNA and Dio1 mRNA were quantified by qPCR in LIRKO and Lox mice (n=10 per group). Bar graphs depict mean±SD. *P<0.05, **P<0.01. mRNA levels of ApoAII, ApoB, ApoCIII, and ApoE, which were reduced in LIRKO mice, were not altered by direct loss of Dio1 expression (Figure V in the online-only Data Supplement). Liver T3 content was actually increased in the D1KO mice compared with wild-type mice ( Figure IVB in the online-only Data Supplement), a result not unexpected based on our prior published studies in these mice. 23, 25 Because LIRKO mice have reduced Dio1 and ApoA-I mRNA levels in association with defective hepatic insulin signaling and insulin resistance, we measured fasting serum insulin levels in D1KO and wild-type mice: there were no differences between the 2 groups (Figure VI in the online-only Data Supplement).
To further understand the effect of Dio1 on normal mice, we knocked down Dio1 expression in C57BL/6J mice using a 16-mer cEt gap-mer antisense oligonucleotide (ASO) that was provided by Ionis Pharmaceuticals. Dio1 and control ASO were administered twice weekly at a dose of 12.5 mg/ kg body weight to 10-week-old C57BL/6J. After 8 weeks of treatment, liver Dio1 mRNA was decreased by 95% ( Figure  VII in the online-only Data Supplement). The reduction in Dio1 expression was associated with a 50% decrease in ApoA-I mRNA ( Figure 2C ) in the mice treated with Dio1 ASO. Serum HDL-C levels and HDL ApoA-I concentrations were both significantly reduced in Dio1 ASO-treated mice compared with controls ASO ( Figure 2D ). The results from both the D1KO mice and the Dio1 ASO-treated mice indicate clearly that Dio1 deficiency results in reduced ApoA-I mRNA levels independent of hepatic insulin signaling and in the presence of normal or elevated hepatic T3 content.
Overexpression of Dio1 Can Restore HDL-C and ApoA-I levels, and Significantly Increase the Expression of ApoA-I in LIRKO Mice
The findings indicated a direct link between Dio1 and ApoA-I expression. To extend these results, we generated an adenovirus containing the cDNA for mouse Dio1 (Ad-Dio1) and injected it into LIRKO mice. LIRKO and Lox mice received Ad-GFP as well. Twelve days after infection, LIRKO mice that had received Ad-Dio1 had an increased expression of hepatic Dio1 ( Figure 3A ) and a significant increase in the expression of hepatic ApoA-I mRNA ( Figure 3B ). Fast protein liquid chromatography profiles showed that LIRKO mice infected with Ad-Dio1 had elevated HDL-C levels compared with LIRKO mice infected with Ad-GFP; LIRKO mice infected with Ad-Dio1 had the same HDL-C levels as Lox mice infected with Ad-GFP ( Figure 3C, top) . Furthermore, immunoblotting of the HDL fractions from the fast protein liquid chromatography profile (fractions 27-33) showed significant increases in ApoA-I in LIRKO mice infected with Ad-Dio1 ( Figure 3C, bottom) . Adenoviralmediated overexpression of Dio1 in C57BL/6J mice had no effects on HDL-C and ApoA-I mRNA levels even though Dio1 mRNA levels increased >2-fold in the C57BL/6J treated with Ad-Dio1 ( Figure VIIIA and VIIIB in the onlineonly Data Supplement). Overall, these data indicate that overexpression of Dio1 corrected the abnormality in hepatic ApoA-I mRNA levels and serum HDL-C and ApoA-I levels in LIRKO mice. The absence of any effect of overexpressing Dio1 in C57BL/6J mice is not surprising in view of the very high levels of D1 in normal mouse livers. 28 
Knockdown of Either InsR or Dio1 Decreases
ApoA-I Expression As Well As the Synthesis and Secretion of ApoA-I in HepG2 Cells
To determine the effects of reduced insulin signaling and Dio1 expression at the cellular level, we used siRNA to knock down either InsR or Dio1 in the human hepatoblastoma cell line, Figure 4C, lanes 1 and 2) . During the 20-minute chase experiment, InsR and Dio1 siRNA-treated cells ( Figure 4C , lanes 9 and 10 and 11 and 12 respectively) secreted 50% or 32% less than control cells ( Figure 4C, lanes  7 and 8) . The similar reductions in synthesis and secretion in each experiment indicated that the reduction in ApoA-I secretion could be fully accounted for by decreased synthesis; there was no evidence of increased intracellular degradation of The ApoA-I promoter region from −256 to −41bp 5′ from the transcription start (+1) has been defined by some investigators as a liver-specific enhancer. It contains 3 transcription factor (TF)-binding regions designated as region A (−256 to −192), region B (−192 to −128), and region C (−128 to −41). 29 We obtained pGL3-luciferase reporter plasmids including a construct containing ApoA-I gene promoter sequence from base pair -256 to +1 and two 5′ deletion constructs as gifts from Professor Bart Staels (France; Figure 5A ). HepG2 cells were transfected with scrambled control siRNA or InsR siRNA for 24 hours, followed by transfection of ABC, BC, or C luciferase reporter constructs of the ApoA-I promoter for another 48 hours. As shown in Figure 5B , knockdown of InsR reduced the activity of the ABC ApoA-I promoter construct by ≈30% of the control level and the activity of the BC ApoA-I promoter construct to ≈50% of control promoter activity. In contrast, knockdown of InsR had no effect on the construct containing only region C of the promoter. These results suggested that region B contained response elements (REs) sensitive to defective insulin signaling. We extended these findings by generating additional ApoA-I promoter constructs containing only region A (A) or region B (B) ( Figure 5C ). Using the same experimental protocol as described above, we demonstrated that defective insulin signaling resulted in decreased ApoA-I promoter activity only through region B ( Figure 5D ). To confirm our earlier findings that defective insulin signaling reduced ApoA-I expression through reduced Dio1 expression, HepG2 cells were transfected with the 3 reporter constructs, A, B or C, after siRNA-mediated knockdown of Dio1. As shown in Figure 5E , knockdown Dio1 reduced the activity of the B promoter construct by ≈35% of the control level, and there were no effects of Dio1 knockdown on either the A or C promoter constructs.
Romney et al 30 had demonstrated that T3 increased ApoA-I gene expression at the level of transcription , and Taylor et al 31 identified region A to contain a positive T3 responsive element in the rat ApoA-I promoter. It was, therefore, important to determine which region(s) of the human ApoA-I promoter is/are responsive to T3 treatment. Because the actions of T3 are mediated by TRβ, HepG2 cells were cotransfected with TRβ and ApoA-I promoter constructs in the presence of T3 or vehicle. As shown in Figure X in the online-only Data Supplement, T3 treatment significantly increased region A promoter activity by ≈35%. Neither region B nor region C was responsive to T3 treatment. These results provide additional evidence that Dio1 is involved in the regulation of the expression of the ApoA-I promoter via effects on Region B, which does not respond to T3 treatment.
Knockdown of Either InsR or Dio1 Reduces the Binding of Nuclear Proteins to Region B and Overexpression of Dio1 Restores That Binding
Based on the results described above, we determined whether defective insulin signaling or decreased Dio1 expression induce 
Discussion
ApoA-I, the major protein component of HDL, is expressed mainly in the liver. Interest in HDL as an antiatherogenic lipoprotein led to extensive interrogation of the regulation of the ApoA-I gene by several groups ≈20 years ago. The proximal region of the ApoA-I promoter, from −256 to −41 bp 5′ of the transcription start region (+1), which has also been called the liver-specific enhancer, was mapped in fine detail and found to contain 3 TF-binding regions that have been designated differently by each group of investigators. 32 We have used the terminology of Vu-Dac et al, 29 who divided the promoter into region A (−256 to −192), region B (−192 to −128), and region C (−128 to −41). Several TFs involved in regulating ApoA-I gene transcription have been identified that bind to REs in ≥1 of these regions. 30, [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] Most relevant to the present studies are the thyroid hormone receptors (TRs) 31 that increase ApoA-I promoter activity by binding to REs in region A.
Despite the longstanding observation that HDL-C and ApoA-I levels are reduced in people with insulin resistance and type 2 diabetes mellitus, studies of the role of insulin signaling on ApoA-I expression have been limited. Elshourbagy et al 43 found that insulin increased the expression of ApoA-I in cultured primary rat hepatocytes. In contrast, Levy et al 44 did not find an effect of insulin on intestinal ApoA-I expression or synthesis, suggesting tissue-specific regulation. Haas et al 45 demonstrated that hepatic ApoA-I mRNA levels were reduced in rats with streptozotocin-induced diabetes, and that insulin's stimulatory activity occurred via binding of the TF, Sp1, to a GC-rich insulin response core element in the region of −411 to −404 bp of the ApoA-I gene promoter upstream from the initiation site. 40 Our results complement those of Haas et al 45 in that defective insulin signaling in LIRKO mice and in HepG2 cells results in reduced ApoA-I expression, synthesis, and secretion. However, we add 2 new and novel findings to prior studies: first, that the effect of absent or reduced hepatic insulin signaling occurs at the level of the ApoA-I promoter at region B of the liver-specific enhancer, between bases −128 and −192 from the transcriptional start region, and second, that the effect of absent or reduced insulin signaling is transmitted to the ApoA-I promoter via reduced expression of hepatic Dio1.
About the effects of absent or reduced hepatic insulin signaling, we have extended our initial finding of low HDL-C levels in LIRKO mice that was corrected by restoration of insulin signaling 21 by demonstrating a similar phenotype in an acute model of InsR knockout. Furthermore, we reproduced these findings in HepG2 cells using a specific siRNA for InsR. Thus, InsR knockdown resulted in reduced expression of ApoA-I that led to lower rates of synthesis and secretion of Apo-AI from HepG2 cells. Finally, as noted above, we demonstrated that the loss of insulin signaling in HepG2 cells resulted in reduced activity of region B of the ApoA-I promoter, and this reduced promoter activity was associated with changes in the binding of nuclear proteins to region B of the ApoA-I promoter.
Our most important novel finding, however, was that the effects of absent or reduced hepatic insulin signaling on ApoA-I expression and promoter activity occurred via insulin signaling-mediated regulation of Dio1. Dio1 is expressed mainly in liver, kidney, thyroid, and pituitary gland, and is the source of D1, a selenoenzyme that can 5′-deiodinate thyroxine (T4) to T3. However, its preferred substrate is 3,3′,5′-triiodothyronine (rT3). The D1 also has inner-ring or 5-deiodinase activity by which it can convert T4 and T3, usually as their sulfated conjugates, to their inactive derivatives, respectively rT3 or 3,3′-T2. 23 The expression of Dio1 is influenced by fasting, severe illness, cytokines, nutritional status, and sex steroids, and it is markedly upregulated by T3. 46 The latter effect probably occurs via 2 thyroid hormone REs (TREs) that have been identified in the regions of −90 to 100 and −660 to 700 bps of the human Dio1 gene 47, 48 although in the rodent gene, T3 stimulates Dio1 expression despite the absence of identifiable TREs in the promoter region. 49 Recently, the TFs Forkhead box A1 and Forkhead box A2 were reported to regulate human Dio1 expression in the liver. 50 Our present studies add hepatic insulin signaling to the list of regulators of Dio1 expression. Thus, both congenital and acute LIRKO mice have marked reductions in Dio1 expression, and the latter abnormality is reversed by delivery of constitutively active AKT. Severe insulin deficiency and metabolic derangements in rats with streptozotocin-induced diabetes mellitus are associated with marked reductions in both Dio1 expression and D1 activity that can be reversed by insulin treatment. 51 In contrast, LIRKO mice have minimally altered metabolism, 21, 52 allowing a more precise demonstration of linkage between defective hepatic insulin signaling and reductions in Dio1 expression. The molecular mechanisms underlying the link between hepatic insulin signaling and downregulation of Dio1 expression will require additional experiments beyond the scope of the present work.
Not only is Dio1 gene expression remarkably reduced in LIRKO mice but also seems to be central to the regulation of ApoA-I gene expression by hepatic insulin signaling. When we overexpressed Dio1 in LIRKO mice, ApoA-I expression and the levels of both plasma HDL-C and ApoA-I increased. Our studies with the D1KO mice and with Dio1 ASO in C57BL/6J mice confirmed the existence of a direct role for Dio1 in the regulation of ApoA-I expression, as well as the levels of plasma HDL-C and ApoA-I. Critical to our model of a direct role of Dio1 in the regulation of ApoA-I expression, the D1KO mice have normal plasma insulin levels indicating normal hepatic insulin signaling. Finally, knockdown of Dio1 by siRNA in HepG2 cells produced the same pattern of nuclear protein binding in an electrophoretic mobility shifted assay as did knockdown of InsR. Importantly, overexpression of Dio1 normalized the pattern of nuclear protein binding in region B in cells where expression of endogenous Dio1 or InsR had been knocked down.
It is well known that thyroid hormone status affects ApoA-I gene expression 26, 27, 53, 54 ; T3 binds to a TRE present in region A via TRs, 55 resulting in increased promoter activity. Furthermore, propylthiouracil, a specific inhibitor of D1 activity, significantly decreased ApoA-I expression and ApoA-I synthesis in rat liver. 53, 56 There is, however, complexity in this pathway, as binding of the T3-TR complex to the other TRE, which is 3′ to the TATA box in region C and close to the transcriptional start-region, leads to decreased promoter activity. 31 In addition, in rodents, unliganded TRs can influence transcription of thyroid responsive genes in the opposite direction than the liganded TR. 57 Our results add another level of complexity: the expression of Dio1 regulates ApoA-I expression at region B, which does not have canonical TREs. Our study that T3 treatment only significantly increased region A promoter activity in the presence of TRβ provided further evidence that region B is not responsive to T3. Additional support for a T3-independent mechanism derives from the finding that hepatic T3 content was normal in LIRKO mice and actually increased in the D1KO mice. These findings were not unexpected based on our previous published data showing a normal content of hepatic T3 in D1KO mice. 25 In addition, both D1KO 23 and C3H mice (which have very low D1 activity due to a naturally occurring mutation in Dio1) 58 seem to be euthyroid in terms of their plasma T3 levels and the expression of several classical T3-responsive genes in the liver. The maintenance of normal or elevated hepatic T3 content in LIRKO and D1KO mice may result from increased delivery of plasma T3 to the liver and reduced conversion of T3 to inactive T2 metabolites when D1 activity is reduced or absent.
Although we have demonstrated that Dio1 acts on the ApoA-I promoter via region B, which does not contain a known TRE, and which is unresponsive to T3 in the presence of adequate TRβ, we have not as yet identified an alternative signaling pathway. Based on existing literature, we know that region B contains REs to which known TFs, including HNF-3β (hepatocyte nuclear factor 3, beta), 38, 42 C/EBP (CCAAT-enhancerbinding proteins), 59 NFY (nuclear transcription factor), 60 or Sp1 61 can bind. How a transmembrane enzyme might interact and activate one of these (or another) TFs that would then act on the ApoA-I promoter, will require significant additional work with approaches that include RNA Seq, transciptomics, and bioinformatics analyses.
In summary, we have demonstrated that hepatic insulin signaling plays a significant role in the regulation of ApoA-I gene expression, as well as the synthesis and secretion of ApoA-I, through the regulation of Dio1. Of note, Dio1-mediated regulation of ApoA-I does not require defective hepatic insulin signaling, as shown by our studies in the D1KO mouse and with Dio1 ASO. Furthermore, loss of Dio1 expression reduces apoA-I expression without affecting expression of several other apolipoproteins that are also reduced when insulin signaling is lost. Our characterization of a novel pathway linking hepatic insulin signaling, Dio1, and ApoA-I, could have significant impact on the problem of low HDL-C in people with metabolic syndrome or type 2 diabetes mellitus. Recent negative CVD clinical trials with fenofibrate, niacin, and cholesteryl ester transfer protein inhibitors, coupled with early but promising results from studies where blood levels of ApoA-I were increased directly, provide impetus for additional studies focused on the molecular mechanisms involved in this pathway. More importantly, identification of the links between Dio1 expression and ApoA-I promoter activity could provide new and significant approaches to regulating plasma HDL-C and ApoA-I levels.
